A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Stopped early · Phase 1

Conditions studied: Non Small Cell Lung Cancer

In brief

The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.

Key facts

Study ID

NCT00461110

Run by

Bristol-Myers Squibb

People needed

35

Starts

2008-01-01

Expected to finish

2009-04-01

Last updated by the study team

2009-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• NSCLC who are eligible to receive a 6 week course of RT
• Part 1 - not candidates for definitive RT
• Part 2 - candidates for definitive RT

You may not qualify if…

• Severe COPD, pulmonary infection or interstitial pneumonitis
• Recent cellulitis
• Autoimmune disease

Where it is running

• The Cancer Institute Of New Jersey — New Brunswick, New Jersey, United States
• Nyu Clinical Cancer Center — New York, New York, United States
• Thomas Jefferson Univ Hospital — Philadelphia, Pennsylvania, United States
• University Of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.